There is a specific kind of AI failure that software companies talk about in general terms: the system gives a confident, plausible-sounding answer that is wrong. In most industries, the consequence is a bad customer experience, a corrected record, maybe some reputational friction. In pharma medical affairs, the consequence can be a regulatory event.
When an MSL cites a specific statistic in a scientific exchange with a physician and that statistic is incorrect, the error does not stay in the room. It potentially flows into a physician's prescribing decision. It potentially becomes part of a documented interaction that a compliance reviewer reads later. In the worst case, it generates an adverse event report or a complaint to a regulatory authority. The standard for acceptable error tolerance is not the same as in most software contexts, and any honest conversation about AI in medical affairs has to start there.
What Hallucination Actually Means in a Pharma Context
Large language models produce text that reads fluently and confidently regardless of whether the underlying claim is accurate. The technical term is hallucination, but it is a somewhat misleading word for what actually happens: the model generates a statistically plausible continuation of a prompt, and plausible is not the same as true.
For general-purpose writing assistance, this is a manageable limitation. A user who asks an AI to draft a blog post can review the output for accuracy. The stakes of a wrong claim in a blog post draft are low enough that a skilled human reviewer catches and corrects errors before they propagate.
Medical affairs is not that context. An MSL using an AI system to look up the observed rate of grade 3 adverse events in a patient subgroup analysis is not draft-reviewing marketing copy. They are looking for the number that is in the document, and they need to know that the number they receive is the number in the document, not a plausible approximation of what a clinical trial result might look like for a drug in this class.
The distinction between "the answer is grounded in the source document" and "the answer is generated by a model that has read many documents" is the entire regulatory question.
The Case for Citation-First Architecture
The response to the hallucination problem in pharma AI cannot be "we have worked hard to reduce hallucination rates." Reduced hallucination is still non-zero hallucination, and non-zero error rates in scientific exchange have regulatory consequences that software improvement timelines do not account for.
The architecture that addresses this problem is citation-first, not answer-first. A citation-first system starts with retrieval: given the user's question, locate the most relevant passages in the indexed document corpus. Then present those passages alongside any synthesized answer, with a direct reference to the source document, section, and page. Any claim is grounded in specific, verifiable text that the user can read in the original source.
This is not just a technical architecture choice. It changes the human workflow around the system. A user who receives an answer plus a citation to the prescribing information, Section 2.4, page 12, can open the prescribing information and read page 12. They are verifying the answer against source, not taking it on faith. That verification step is the compliance control, and it is a human control that the system makes possible rather than one the system tries to replace.
Why the Verification Step Must Stay With a Human
There is a tempting design direction in AI for medical affairs: building systems that automate the verification step. A system that not only retrieves an answer but validates it against the label, flags whether the claim falls within the approved indication, and generates a compliant response ready for an HCP interaction.
We think that design direction is wrong for this stage of the technology and wrong for this regulatory environment, and not primarily for technical reasons.
FDA's evolving thinking on AI in clinical contexts distinguishes between decision support tools and tools that substitute human clinical judgment. The former augments a qualified professional. The latter substitutes for them. Medical affairs teams operate in a context where the boundary between scientific information exchange and clinical advice is already closely supervised by compliance and legal. Automating the judgment call about what content is appropriate for a specific physician in a specific interaction crosses a line that has not been formally cleared.
The human-in-the-loop requirement is not a conservative stance adopted out of caution. It is the accurate description of what responsible operation looks like in this environment right now, given where the regulatory framework sits.
How Source Grounding Changes the Error Profile
A citation-first system does not eliminate error. It changes the error profile in two important ways.
First, errors become attributable. When an AI system returns an answer and a citation, and the user reads the cited passage, any discrepancy between the answer and the passage is visible to the user. The error surface is transparent. An answer-only system that hallucinates a statistic produces an error that the user has no immediate way to detect. A citation-first system that misreads a table produces an error the user catches when they read the table.
Second, errors become traceable. In a regulated environment where scientific exchange interactions are documented, an MSL who can show that their data point came from a specific section of a specific document version is demonstrating a traceable chain from source to claim. An MSL who used an AI system that generated an answer without attribution has a harder time reconstructing where that answer came from during a compliance review.
Neither of these is a complete solution. Attributable and traceable errors are still errors. But the compliance infrastructure that medical affairs teams operate within is designed around attributable, traceable documentation chains, and a source-grounded retrieval system fits that infrastructure in a way that an answer-only generative system does not.
The Broader Pattern in Regulated Industries
Pharma is not the only regulated industry asking these questions. Legal, financial services, and clinical research organizations are all working through the same tension: AI systems that are genuinely useful for information work, operating in contexts where the error cost is high and the audit requirement is real.
The pattern that is emerging across these industries is consistent with what we built Argon to do: the AI component handles retrieval and surface; the human professional applies judgment and verification; the documentation layer captures what was retrieved from where, so the chain can be reconstructed later.
This is not a temporary arrangement while AI matures. It is the appropriate architecture for contexts where a wrong answer has consequences that extend past the immediate interaction. In pharma medical affairs, those consequences include physician prescribing decisions and regulatory scrutiny. Source grounding is not a differentiating feature in that context. It is the minimum viable design for responsible deployment.